Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia Roxburgh

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Current Oncology Reports|October 26, 2014
Squamous carcinoma of the ovaryPatricia Roxburgh, Rosalind Glasspool
Advances in Therapy|October 31, 2008
Systemic therapy of hepatocellular carcinoma: are we making progress?Patricia Roxburgh, T R Jeffry Evans
Future Oncology (London, England)|May 31, 2013
How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?Colin R Lindsay, Patricia Roxburgh, Janet Graham
Journal of Immunotherapy and Precision Oncology|June 6, 2022
First-Line PARP Inhibitors-Emerging Side Effects Require Caution: A Case of PARPi-Induced PneumonitisAlistair McLaren, Douglas Cartwright, Ewen Ross, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 21, 2013
Concerning the feasibility of obtaining biopsies for research in relapsed ovarian cancerPatricia Roxburgh, Gordon W Cowell, Rosalind M Glasspool
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 9, 2025
Controversies in the management of serous borderline tumors and low-grade serous ovarian cancerNarthana Ilenkovan, Neil Ryan, Patricia Roxburgh, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 21, 2021
Metronomic oral cyclophosphamide in relapsed ovarian cancerPavlina Spiliopoulou, Samantha Hinsley, Iain A McNeish, et al.
Plos One|June 3, 2014
iRFP is a real time marker for transformation based assays in high content screeningViola Paulus-Hock, Eric C Cheung, Patricia Roxburgh, et al.
Carcinogenesis|February 4, 2012
Small molecules that bind the Mdm2 RING stabilize and activate p53Patricia Roxburgh, Andreas K Hock, Michael P Dickens, et al.
Bioorganic & Medicinal Chemistry|October 12, 2013
5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2Michael P Dickens, Patricia Roxburgh, Andreas Hock, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Current Oncology Reports|October 26, 2014
Squamous carcinoma of the ovaryPatricia Roxburgh, Rosalind Glasspool
Advances in Therapy|October 31, 2008
Systemic therapy of hepatocellular carcinoma: are we making progress?Patricia Roxburgh, T R Jeffry Evans
Future Oncology (London, England)|May 31, 2013
How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?Colin R Lindsay, Patricia Roxburgh, Janet Graham
Journal of Immunotherapy and Precision Oncology|June 6, 2022
First-Line PARP Inhibitors-Emerging Side Effects Require Caution: A Case of PARPi-Induced PneumonitisAlistair McLaren, Douglas Cartwright, Ewen Ross, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 21, 2013
Concerning the feasibility of obtaining biopsies for research in relapsed ovarian cancerPatricia Roxburgh, Gordon W Cowell, Rosalind M Glasspool
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 9, 2025
Controversies in the management of serous borderline tumors and low-grade serous ovarian cancerNarthana Ilenkovan, Neil Ryan, Patricia Roxburgh, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 21, 2021
Metronomic oral cyclophosphamide in relapsed ovarian cancerPavlina Spiliopoulou, Samantha Hinsley, Iain A McNeish, et al.
Plos One|June 3, 2014
iRFP is a real time marker for transformation based assays in high content screeningViola Paulus-Hock, Eric C Cheung, Patricia Roxburgh, et al.
Carcinogenesis|February 4, 2012
Small molecules that bind the Mdm2 RING stabilize and activate p53Patricia Roxburgh, Andreas K Hock, Michael P Dickens, et al.
Bioorganic & Medicinal Chemistry|October 12, 2013
5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2Michael P Dickens, Patricia Roxburgh, Andreas Hock, et al.
Pageof 4